Drug class
Overactive Bladder Agents-Beta 3 Adrenergic Receptor Agonist
Overactive bladder agents in the beta-3 adrenergic receptor agonist class are urological pharmacotherapies that selectively stimulate beta-3 adrenergic receptors located in the detrusor smooth muscle of the bladder wall. Read more about Overactive Bladder Agents-Beta 3 Adrenergic Receptor Agonist
8 drugs in this class 8 manufacturers
Drugs in Overactive Bladder Agents-Beta 3 Adrenergic Receptor Agonist
GEMTESA (vibegron)
MIRABEGRON ER (mirabegron)
MIRABEGRON ER (mirabegron)
MYRBETRIQ (mirabegron)
MIRABEGRON ER (mirabegron)
MIRABEGRON ER (mirabegron)
MIRABEGRON ER (mirabegron)
Overactive bladder agents in the beta-3 adrenergic receptor agonist class are urological pharmacotherapies that selectively stimulate beta-3 adrenergic receptors located in the detrusor smooth muscle of the bladder wall.
This receptor activation induces detrusor muscle relaxation during the storage phase of the micturition cycle, thereby increasing bladder capacity without suppressing voiding contractions.
The class is primarily indicated for the treatment of overactive bladder characterized by symptoms of urge urinary incontinence, urgency, and urinary frequency, and certain agents are also utilized for neurogenic detrusor overactivity.
-
fda.gov
Overactive bladder agents in the beta-3 adrenergic receptor agonist class are urological pharmacotherapies that selectively stimulate beta-3 adrenergic receptors located in the detrusor smooth muscle of the bladder wall
-
nih.gov
Overactive bladder agents in the beta-3 adrenergic receptor agonist class are urological pharmacotherapies that selectively stimulate beta-3 adrenergic receptors located in the detrusor smooth muscle of the bladder wall The class is primarily indicated for the treatment of overactive bladder characterized by symptoms of urge urinary incontinence, urgency, and urinary frequency, and certain agents are also utilized for neurogenic detrusor overactivity
-
fda.gov
This receptor activation induces detrusor muscle relaxation during the storage phase of the micturition cycle, thereby increasing bladder capacity without suppressing voiding contractions
-
urologytimes.com
This receptor activation induces detrusor muscle relaxation during the storage phase of the micturition cycle, thereby increasing bladder capacity without suppressing voiding contractions
-
fda.gov
The class is primarily indicated for the treatment of overactive bladder characterized by symptoms of urge urinary incontinence, urgency, and urinary frequency, and certain agents are also utilized for neurogenic detrusor overactivity
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.